Yes there has been some nibbling by institutional investors but more of the specialized funds (healthcare) as the volume is obviosly low & showing limited accumulation.. One of the primary players in the stock---institutional biotech leader Cowen & Co. who's the axe on the stock institutionally---has been out marketing THLD to accounts in US & Europe. They see the stock in the double digits this year as the upcoming results lend comfort to a higher valuation. It's a shame THLDthey gave up marketing rights to MerckAG but it was a safe call. Without that the stock would likely be double digits now. But at $300mm+ market cap with large billion $$ market opportunities on the horizon one can make a very plausible case for THLD to be a $20-30 stock over the next couple of years.